Baxter International Inc
NYSE:BAX
Gross Margin
Baxter International Inc
Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.
Gross Margin Across Competitors
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| US |
|
Baxter International Inc
NYSE:BAX
|
15.5B USD |
38%
|
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
224.5B USD |
56%
|
|
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
184.2B USD |
67%
|
|
| US |
|
Boston Scientific Corp
NYSE:BSX
|
151B USD |
69%
|
|
| US |
|
Stryker Corp
NYSE:SYK
|
140.2B USD |
64%
|
|
| IE |
|
Medtronic PLC
NYSE:MDT
|
107.8B USD |
66%
|
|
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
52.9B EUR |
38%
|
|
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
59.8B USD |
45%
|
|
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
44.7B USD |
79%
|
|
| CN |
|
Shenzhen Mindray Bio-Medical Electronics Co Ltd
SZSE:300760
|
260.4B CNY |
64%
|
|
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
35.5B USD |
61%
|
Baxter International Inc
Glance View
Baxter International Inc. finds its roots in the early 1930s, a time when the healthcare landscape was vastly different. Founded by Donald Baxter, a medical doctor seeking to improve the quality and safety of intravenous therapy, the company initially focused on researching and developing safe ways to provide patients with sterile intravenous solutions. As the years unfolded, Baxter transformed itself from a small operation into a globally recognized healthcare giant. Today, it operates in the realm of lifesaving medical products and services, specializing in the development of essential pharmaceuticals, clinical nutrition for hospitals, advanced kidney care solutions, and critical care technology that healthcare providers depend on daily. Central to Baxter's business model is its commitment to innovation and improving patient outcomes, which drives its success and profitability. By leveraging its expertise in areas like renal and hospital products, Baxter is able to cultivate a diversified portfolio. This diversification not only helps the company mitigate risks but also strengthens its market position. Revenue streams are generated through the manufacture and sale of medical devices and pharmaceuticals, catering mostly to hospitals, clinics, and renal care centers worldwide. Baxter consistently reinvests in its research and development, aiming to pioneer novel therapies and products that address the evolving needs of the healthcare sector, ensuring that it remains a key player in the ongoing story of medical progress.
See Also
Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.
Based on Baxter International Inc's most recent financial statements, the company has Gross Margin of 38%.
You don't have any saved screeners yet